JP2015520606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520606A5 JP2015520606A5 JP2015505034A JP2015505034A JP2015520606A5 JP 2015520606 A5 JP2015520606 A5 JP 2015520606A5 JP 2015505034 A JP2015505034 A JP 2015505034A JP 2015505034 A JP2015505034 A JP 2015505034A JP 2015520606 A5 JP2015520606 A5 JP 2015520606A5
- Authority
- JP
- Japan
- Prior art keywords
- maf
- gene
- breast cancer
- expression level
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100039189 Transcription factor Maf Human genes 0.000 claims 39
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 238000000034 method Methods 0.000 claims 21
- 230000014509 gene expression Effects 0.000 claims 19
- 210000000988 bone and bone Anatomy 0.000 claims 18
- 206010027476 Metastases Diseases 0.000 claims 15
- 230000009401 metastasis Effects 0.000 claims 15
- 206010006187 Breast cancer Diseases 0.000 claims 12
- 208000026310 Breast neoplasm Diseases 0.000 claims 12
- 238000000338 in vitro Methods 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102000014128 RANK Ligand Human genes 0.000 claims 5
- 108010025832 RANK Ligand Proteins 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 230000003321 amplification Effects 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 230000015556 catabolic process Effects 0.000 claims 3
- 238000006731 degradation reaction Methods 0.000 claims 3
- 208000026535 luminal A breast carcinoma Diseases 0.000 claims 3
- 208000026534 luminal B breast carcinoma Diseases 0.000 claims 3
- 230000005945 translocation Effects 0.000 claims 3
- 229940122361 Bisphosphonate Drugs 0.000 claims 2
- 102000055006 Calcitonin Human genes 0.000 claims 2
- 108060001064 Calcitonin Proteins 0.000 claims 2
- 229940097000 DKK-1 inhibitor Drugs 0.000 claims 2
- 101001135738 Homo sapiens Parathyroid hormone-related protein Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 206010027452 Metastases to bone Diseases 0.000 claims 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims 2
- 102100036899 Parathyroid hormone-related protein Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- QHLITPHIARVDJI-UHFFFAOYSA-N [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC(C=2C=C3C=CC=CC3=CC=2)=N1 QHLITPHIARVDJI-UHFFFAOYSA-N 0.000 claims 2
- 150000004663 bisphosphonates Chemical class 0.000 claims 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 2
- 229960004015 calcitonin Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 claims 2
- 229960005562 radium-223 Drugs 0.000 claims 2
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 claims 2
- 229940079488 strontium ranelate Drugs 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 102000004171 Cathepsin K Human genes 0.000 claims 1
- 108090000625 Cathepsin K Proteins 0.000 claims 1
- 229940122156 Cathepsin K inhibitor Drugs 0.000 claims 1
- 230000004544 DNA amplification Effects 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 208000003076 Osteolysis Diseases 0.000 claims 1
- 102000008108 Osteoprotegerin Human genes 0.000 claims 1
- 108010035042 Osteoprotegerin Proteins 0.000 claims 1
- 208000020584 Polyploidy Diseases 0.000 claims 1
- 102000001332 SRC Human genes 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 229940125436 dual inhibitor Drugs 0.000 claims 1
- 238000011337 individualized treatment Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 108010087686 src-Family Kinases Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621949P | 2012-04-09 | 2012-04-09 | |
| EP12382139.9A EP2650682A1 (en) | 2012-04-09 | 2012-04-09 | Method for the prognosis and treatment of cancer metastasis |
| US61/621,949 | 2012-04-09 | ||
| EP12382139.9 | 2012-04-09 | ||
| US201261724807P | 2012-11-09 | 2012-11-09 | |
| US61/724,807 | 2012-11-09 | ||
| US201261732175P | 2012-11-30 | 2012-11-30 | |
| US61/732,175 | 2012-11-30 | ||
| PCT/IB2013/001204 WO2013153458A2 (en) | 2012-04-09 | 2013-03-15 | Method for the prognosis and treatment of cancer metastasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018059907A Division JP6781184B2 (ja) | 2012-04-09 | 2018-03-27 | がん転移の予後診断および処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520606A JP2015520606A (ja) | 2015-07-23 |
| JP2015520606A5 true JP2015520606A5 (cg-RX-API-DMAC10.html) | 2016-05-12 |
| JP6381519B2 JP6381519B2 (ja) | 2018-08-29 |
Family
ID=45929479
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505034A Active JP6381519B2 (ja) | 2012-04-09 | 2013-03-15 | がん転移の予後診断および処置のための方法 |
| JP2018059907A Active JP6781184B2 (ja) | 2012-04-09 | 2018-03-27 | がん転移の予後診断および処置のための方法 |
| JP2020174192A Withdrawn JP2021007408A (ja) | 2012-04-09 | 2020-10-15 | がん転移の予後診断および処置のための方法 |
| JP2022099476A Pending JP2022125079A (ja) | 2012-04-09 | 2022-06-21 | がん転移の予後診断および処置のための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018059907A Active JP6781184B2 (ja) | 2012-04-09 | 2018-03-27 | がん転移の予後診断および処置のための方法 |
| JP2020174192A Withdrawn JP2021007408A (ja) | 2012-04-09 | 2020-10-15 | がん転移の予後診断および処置のための方法 |
| JP2022099476A Pending JP2022125079A (ja) | 2012-04-09 | 2022-06-21 | がん転移の予後診断および処置のための方法 |
Country Status (13)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| EP3467124A1 (en) | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| CA2888122A1 (en) * | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20160032399A1 (en) * | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| KR20150122786A (ko) | 2013-03-15 | 2015-11-02 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 암 전이의 진단, 예후 및 치료를 위한 방법 |
| US20160032400A1 (en) * | 2013-03-15 | 2016-02-04 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| EP3524698A1 (en) * | 2013-10-09 | 2019-08-14 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| KR20170093182A (ko) * | 2014-12-11 | 2017-08-14 | 인바이오모션 에스.엘. | 인간 c-maf에 대한 결합 구성원 |
| US20180104232A1 (en) * | 2015-03-12 | 2018-04-19 | The University Of Chicago | Methods for determining prognosis for breast cancer patients |
| ES2883249T3 (es) * | 2015-03-17 | 2021-12-07 | Mayo Found Medical Education & Res | Métodos y materiales para evaluar y tratar el cáncer |
| EP3347720A1 (en) * | 2015-09-09 | 2018-07-18 | Somalogic, Inc. | Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles |
| MA44733A (fr) * | 2016-04-19 | 2019-02-27 | Exelixis Inc | Procédé de traitement du cancer du sein négatif triple |
| CA3025264A1 (en) * | 2016-05-25 | 2017-11-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| CN105907886A (zh) * | 2016-07-07 | 2016-08-31 | 蔡维泺 | miR-124在乳腺癌骨转移疾病中的应用 |
| WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
| CN108796071A (zh) * | 2017-04-26 | 2018-11-13 | 中国科学院上海生命科学研究院 | 转移性乳腺癌标记物及其在诊断和治疗中的应用 |
| CA3082728A1 (en) | 2017-11-22 | 2019-05-31 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| KR102664243B1 (ko) * | 2018-01-19 | 2024-05-08 | 데루타-후라이 화마 가부시키가이샤 | 암 환자의 치료에 유용한 오줌의 알칼리제 |
| KR102224910B1 (ko) * | 2018-06-26 | 2021-03-05 | 재단법인 의약바이오컨버젼스연구단 | Rna 은 제자리 혼성화 방법을 통한 aimp2-dx2 신호 자동화 검출 방법 |
| CN110656171B (zh) * | 2018-06-28 | 2023-05-05 | 润安医学科技(苏州)有限公司 | 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途 |
| EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| WO2020102513A1 (en) * | 2018-11-14 | 2020-05-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems and methods for characterizing and treating cancer |
| WO2021062261A1 (en) * | 2019-09-25 | 2021-04-01 | The Trustees Of Columbia University In The City Of New York | Prognostic markers of metastatic cancer |
| CN112662763A (zh) * | 2020-03-10 | 2021-04-16 | 博尔诚（北京）科技有限公司 | 一种检测常见两性癌症的探针组合物 |
| CN112662764A (zh) * | 2020-03-17 | 2021-04-16 | 博尔诚（北京）科技有限公司 | 一种检测11种癌症的探针组合物 |
| JP7607330B2 (ja) * | 2021-04-30 | 2024-12-27 | 国立大学法人金沢大学 | 骨腫瘍の予後診断方法又は予後診断補助方法 |
| EP4358955A4 (en) * | 2021-06-21 | 2025-01-08 | Palvella Therapeutics, Inc. | Methods and compositions for treating gorlin syndrome |
| IT202200001817A1 (it) | 2022-02-02 | 2023-08-02 | Aizoon S R L | Procedimento per la prognosi di una malattia in seguito ad un trattamento terapeutico, relativo sistema e prodotto informatico |
| US20250161287A1 (en) * | 2022-02-18 | 2025-05-22 | Vuja De Sciences, Inc. | Methods, compositions, and combinations for preventing or treating cancer recurrence |
| IT202200005861A1 (it) | 2022-03-24 | 2023-09-24 | Aizoon S R L | Procedimento per stimare una variabile di interesse associata ad una data malattia in funzione di una pluralità di diversi dati omici, relativo dispositivo e prodotto informatico |
| US20240028964A1 (en) | 2022-07-25 | 2024-01-25 | Aizoon S.r.l. | Method for providing a clinical decision support, corresponding system for providing a clinical decision support, and computer program product |
| CN115919464B (zh) * | 2023-03-02 | 2023-06-23 | 四川爱麓智能科技有限公司 | 肿瘤定位方法、系统、装置及肿瘤发展预测方法 |
| CN119614707A (zh) * | 2025-01-13 | 2025-03-14 | 中山大学 | ERα生物标志物在ER+乳腺癌骨转移诊断、治疗和预后中的应用 |
| CN119662833B (zh) * | 2025-01-22 | 2025-08-15 | 中山大学孙逸仙纪念医院 | 基于肿瘤小泡中circCCDC50的Luminal型乳腺癌骨转移标记物、预测诊断试剂盒 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE89314T1 (de) | 1985-02-13 | 1993-05-15 | Scios Nova Inc | Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen. |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| DE4013632A1 (de) | 1990-04-27 | 1991-10-31 | Max Planck Gesellschaft | Liposomen mit positiver ueberschussladung |
| EP0910652B1 (en) | 1996-04-05 | 2014-10-08 | The Salk Institute For Biological Studies | Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| ATE497001T1 (de) | 1996-12-23 | 2011-02-15 | Immunex Corp | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| US6274338B1 (en) | 1998-02-24 | 2001-08-14 | President And Fellows Of Harvard College | Human c-Maf compositions and methods of use thereof |
| EA200100972A1 (ru) | 1999-03-15 | 2002-02-28 | Аксис Фармасьютикалз, Инк. | Новые соединения и композиции как ингибиторы протеаз |
| TW404030B (en) | 1999-04-12 | 2000-09-01 | Siliconware Precision Industries Co Ltd | Dual-chip semiconductor package device having malposition and the manufacture method thereof |
| US6287813B1 (en) | 1999-04-23 | 2001-09-11 | Cistronics Cell Technology Gmbh | Antibiotic-based gene regulation system |
| DE60132975T2 (de) | 2000-01-06 | 2009-02-26 | Merck Frosst Canada Inc., Kirkland | Neue substanzen und verbindungen als protease-inhibitoren |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| KR100485271B1 (ko) | 2002-01-16 | 2005-04-27 | 메타볼랩(주) | 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물 |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| DE10235624A1 (de) | 2002-08-02 | 2004-02-19 | Aventis Pharma Deutschland Gmbh | Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben |
| US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| WO2005026322A2 (en) | 2003-09-11 | 2005-03-24 | Clontech Laboratories, Inc. | siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME |
| CN1898563B (zh) | 2003-09-24 | 2011-11-23 | 肿瘤疗法科学股份有限公司 | 诊断乳腺癌的方法 |
| AU2003286499A1 (en) | 2003-10-17 | 2004-06-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Interference with c-maf function in multiple myeloma |
| WO2005060722A2 (en) | 2003-12-18 | 2005-07-07 | President And Fellows Of Hardvard College | Modulation of immune system function by modulation of polypeptide arginine methyltransferases |
| TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
| EP1730308A4 (en) * | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS |
| US20080131940A1 (en) | 2004-06-25 | 2008-06-05 | Robert Chiu | Target Cell-Specific Short Interfering Rna and Methods of Use Thereof |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| CA2623405C (en) | 2005-09-20 | 2014-11-25 | Immunivest Corporation | Methods and composition to generate unique sequence dna probes labeling of dna probes and the use of these probes |
| US20080219996A1 (en) | 2005-09-26 | 2008-09-11 | Thea Kalebic | Molecular Markers Associated with Bone Metastasis |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US8173825B2 (en) | 2006-12-20 | 2012-05-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Method of making fatty acid ester derivatives |
| WO2008098351A1 (en) | 2007-02-14 | 2008-08-21 | University Health Network | Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| CA2688049A1 (en) | 2007-05-31 | 2008-12-04 | Dako Denmark A/S | Methods for utilizing esr copy number changes in breast cancer treatments and prognoses |
| NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| AU2008314459A1 (en) | 2007-10-18 | 2009-04-23 | University Health Network | Clioquinol for the treatment of hematological malignancies |
| WO2009114534A1 (en) | 2008-03-14 | 2009-09-17 | The Regents Of The University Of California | Multi-gene classifiers and prognostic indicators for cancers |
| US20110144155A1 (en) | 2008-06-06 | 2011-06-16 | Schimmer Aaron D | 8-hydroxyquinoline derivatives for the treatment of hematological malignancies |
| ES2338843B1 (es) | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Huella genomica de cancer de mama. |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| US20120121586A1 (en) | 2009-05-29 | 2012-05-17 | Astrid Kiermaier | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| EP2486149B1 (en) | 2009-08-06 | 2015-06-17 | John Wayne Cancer Institute | Diagnosis of primary and metastatic basal-like breast cancer and other cancer types |
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| AU2012211964A1 (en) | 2011-02-04 | 2013-08-22 | Bioarray Genetics, Inc. | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment |
| JP5971769B2 (ja) | 2011-03-15 | 2016-08-17 | ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル | アントラサイクリン療法を用いて乳癌を処置する方法 |
| EP2780469A1 (en) | 2011-11-18 | 2014-09-24 | Vanderbilt University | Markers of triple-negative breast cancer and uses thereof |
| EP2650682A1 (en) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| EP3467124A1 (en) | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| CA2888122A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| KR20150122786A (ko) | 2013-03-15 | 2015-11-02 | 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) | 암 전이의 진단, 예후 및 치료를 위한 방법 |
| US20160032400A1 (en) | 2013-03-15 | 2016-02-04 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| EP3524698A1 (en) | 2013-10-09 | 2019-08-14 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| KR20170093182A (ko) | 2014-12-11 | 2017-08-14 | 인바이오모션 에스.엘. | 인간 c-maf에 대한 결합 구성원 |
| CA3025264A1 (en) | 2016-05-25 | 2017-11-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| CA3082728A1 (en) | 2017-11-22 | 2019-05-31 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
-
2012
- 2012-04-09 EP EP12382139.9A patent/EP2650682A1/en not_active Withdrawn
-
2013
- 2013-03-15 ES ES20170652T patent/ES2995194T3/es active Active
- 2013-03-15 WO PCT/IB2013/001204 patent/WO2013153458A2/en not_active Ceased
- 2013-03-15 CA CA2891609A patent/CA2891609C/en active Active
- 2013-03-15 DK DK20170652.0T patent/DK3825692T3/da active
- 2013-03-15 US US14/391,085 patent/US9702878B2/en active Active
- 2013-03-15 JP JP2015505034A patent/JP6381519B2/ja active Active
- 2013-03-15 AU AU2013246618A patent/AU2013246618B9/en active Active
- 2013-03-15 EP EP13731875.4A patent/EP2836837B1/en active Active
- 2013-03-15 MX MX2014012233A patent/MX374827B/es active IP Right Grant
- 2013-03-15 ES ES13731875T patent/ES2798107T3/es active Active
- 2013-03-15 KR KR1020147031148A patent/KR102252332B1/ko active Active
- 2013-03-15 BR BR112014025269-6A patent/BR112014025269B1/pt active IP Right Grant
- 2013-03-15 CN CN201380027292.1A patent/CN104797935B/zh active Active
- 2013-03-15 KR KR1020217014022A patent/KR102442275B1/ko active Active
- 2013-03-15 DK DK13731875.4T patent/DK2836837T3/da active
- 2013-03-15 EP EP20170652.0A patent/EP3825692B1/en active Active
- 2013-03-15 FI FIEP20170652.0T patent/FI3825692T3/fi active
-
2017
- 2017-05-30 US US15/608,036 patent/US10866241B2/en active Active
-
2018
- 2018-03-27 JP JP2018059907A patent/JP6781184B2/ja active Active
-
2020
- 2020-10-15 JP JP2020174192A patent/JP2021007408A/ja not_active Withdrawn
- 2020-12-01 US US17/108,390 patent/US12196758B2/en active Active
-
2022
- 2022-06-21 JP JP2022099476A patent/JP2022125079A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015521050A5 (cg-RX-API-DMAC10.html) | ||
| Sideris et al. | LncRNAs in breast cancer: a link to future approaches | |
| Nie et al. | Long non-coding RNA MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion | |
| Salvador et al. | From latency to overt bone metastasis in breast cancer: potential for treatment and prevention | |
| Riester et al. | The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation | |
| Ruiz-Saenz et al. | A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors | |
| Thomas et al. | Expression profiling of cervical cancers in I ndian women at different stages to identify gene signatures during progression of the disease | |
| Yue et al. | LncRNA‐ATB mediated E‐cadherin repression promotes the progression of colon cancer and predicts poor prognosis | |
| Kuiper et al. | Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients | |
| Salendo et al. | Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a,-224,-132 and let7g | |
| Zhang et al. | Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a | |
| Cao et al. | miR-125a-5p post-transcriptionally suppresses GALNT7 to inhibit proliferation and invasion in cervical cancer cells via the EGFR/PI3K/AKT pathway | |
| Cui et al. | LncRNA FAM230B promotes gastric cancer growth and metastasis by regulating the miR-27a-5p/TOP2A axis | |
| Turato et al. | SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis | |
| JP2016539625A5 (cg-RX-API-DMAC10.html) | ||
| Ejaeidi et al. | Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis | |
| Liu et al. | ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness | |
| JP2016516403A5 (cg-RX-API-DMAC10.html) | ||
| Sestito et al. | miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma | |
| Sethi et al. | MicroRNAs in personalized cancer therapy | |
| JP2016105731A5 (cg-RX-API-DMAC10.html) | ||
| Witkiewicz et al. | Towards a new “stromal-based” classification system for human breast cancer prognosis and therapy | |
| BR112014025269A2 (pt) | método para o prognóstico e tratamento de metástase de câncer | |
| Yu et al. | RETRACTED: MiR-144 suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SMAD4 | |
| JP2013541339A5 (cg-RX-API-DMAC10.html) |